Cohen Joshua B 4

What Happened
Joshua B. Cohen, CEO of Amylyx Pharmaceuticals (AMLX), sold 15,500 shares on February 2, 2026, realizing approximately $227,593. The reported weighted-average sale price was $14.68 per share (individual trade prices ranged $14.510–$14.760). This was a sale (S) tied to tax withholding on vested restricted stock units and was automatic—not an open discretionary sell for investment reasons.

Key Details

• Transaction date: 2026-02-02 (reported on Form 4 filed 2026-02-04).
• Price: weighted average $14.68; trades ranged from $14.510 to $14.760.
• Shares sold: 15,500; proceeds ≈ $227,593.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes: F1 = sale required to cover tax withholding on vesting RSUs (automatic); F2 = weighted-average price, multiple transactions.
• Timeliness: Filed Feb 4, 2026 for a Feb 2 transaction—no late filing indicated.

Context
Sales to cover tax withholding on vested awards are routine and automatic and do not necessarily indicate a CEO’s view on the company’s prospects. This was not reported as part of a 10b5-1 plan or an opportunistic open-market purchase; it was a tax-withholding disposition related to RSU vesting.